Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 76 entries
Sorted by: Best Match Show Resources per page
Systemic side effects of eye drops: a pharmacokinetic perspective.

Clinical ophthalmology (Auckland, N.Z.)

Farkouh A, Frigo P, Czejka M.
PMID: 27994437
Clin Ophthalmol. 2016 Dec 07;10:2433-2441. doi: 10.2147/OPTH.S118409. eCollection 2016.

When administering eye drops, even when completely correctly applied, several routes of absorption are possible and excess amounts can sometimes cause an unwanted systemic bioavailability of the drops when not completely absorbed into the eye. Furthermore, the concentration of...

Cite
Farkouh A, Frigo P, Czejka M. Systemic side effects of eye drops: a pharmacokinetic perspective. Clin Ophthalmol. 2016;10:2433-2441doi: 10.2147/OPTH.S118409.
Farkouh, A., Frigo, P., & Czejka, M. (2016). Systemic side effects of eye drops: a pharmacokinetic perspective. Clinical ophthalmology (Auckland, N.Z.), 102433-2441. https://doi.org/10.2147/OPTH.S118409
Farkouh, Andre, et al. "Systemic side effects of eye drops: a pharmacokinetic perspective." Clinical ophthalmology (Auckland, N.Z.) vol. 10 (2016): 2433-2441. doi: https://doi.org/10.2147/OPTH.S118409
Farkouh A, Frigo P, Czejka M. Systemic side effects of eye drops: a pharmacokinetic perspective. Clin Ophthalmol. 2016 Dec 07;10:2433-2441. doi: 10.2147/OPTH.S118409. eCollection 2016. PMID: 27994437; PMCID: PMC5153265.
Copy Download .nbib Format: NLM
ACP Journal Club. Nateglinide did not reduce diabetes or CV events in patients with impaired glucose tolerance and CV risk factors.

Annals of internal medicine

Farkouh M.
PMID: 20547892
Ann Intern Med. 2010 Jun 15;152(12):JC6-10. doi: 10.7326/0003-4819-152-12-201006150-02010.

No abstract available.

Cite
Farkouh M. ACP Journal Club. Nateglinide did not reduce diabetes or CV events in patients with impaired glucose tolerance and CV risk factors. Ann Intern Med. 2010;152(12):JC6-10doi: 10.7326/0003-4819-152-12-201006150-02010.
Farkouh, M. (2010). ACP Journal Club. Nateglinide did not reduce diabetes or CV events in patients with impaired glucose tolerance and CV risk factors. Annals of internal medicine, 152(12), JC6-10. https://doi.org/10.7326/0003-4819-152-12-201006150-02010
Farkouh, Michael. "ACP Journal Club. Nateglinide did not reduce diabetes or CV events in patients with impaired glucose tolerance and CV risk factors." Annals of internal medicine vol. 152,12 (2010): JC6-10. doi: https://doi.org/10.7326/0003-4819-152-12-201006150-02010
Farkouh M. ACP Journal Club. Nateglinide did not reduce diabetes or CV events in patients with impaired glucose tolerance and CV risk factors. Ann Intern Med. 2010 Jun 15;152(12):JC6-10. doi: 10.7326/0003-4819-152-12-201006150-02010. PMID: 20547892.
Copy Download .nbib Format: NLM
Lumiracoxib, a highly selective COX-2 inhibitor.

Expert review of clinical immunology

Jeger RV, Greenberg JD, Ramanathan K, Farkouh ME.
PMID: 20477653
Expert Rev Clin Immunol. 2005 May;1(1):37-45. doi: 10.1586/1744666X.1.1.37.

Lumiracoxib Prexige, Novartis AG) is a highly selective inhibitor of cyclooxygenase-2 that has been approved in 22 countries including the UK for analgesic therapy in chronic and acute pain. For patients with osteoarthritis, the recommended initial dose is 100...

Cite
Jeger RV, Greenberg JD, Ramanathan K, et al. Lumiracoxib, a highly selective COX-2 inhibitor. Expert Rev Clin Immunol. 2005;1(1):37-45doi: 10.1586/1744666X.1.1.37.
Jeger, R. V., Greenberg, J. D., Ramanathan, K., & Farkouh, M. E. (2005). Lumiracoxib, a highly selective COX-2 inhibitor. Expert review of clinical immunology, 1(1), 37-45. https://doi.org/10.1586/1744666X.1.1.37
Jeger, Raban V, et al. "Lumiracoxib, a highly selective COX-2 inhibitor." Expert review of clinical immunology vol. 1,1 (2005): 37-45. doi: https://doi.org/10.1586/1744666X.1.1.37
Jeger RV, Greenberg JD, Ramanathan K, Farkouh ME. Lumiracoxib, a highly selective COX-2 inhibitor. Expert Rev Clin Immunol. 2005 May;1(1):37-45. doi: 10.1586/1744666X.1.1.37. PMID: 20477653.
Copy Download .nbib Format: NLM
Mini-review: medication safety of red yeast rice products.

International journal of general medicine

Farkouh A, Baumgärtel C.
PMID: 31118742
Int J Gen Med. 2019 Apr 30;12:167-171. doi: 10.2147/IJGM.S202446. eCollection 2019.

High lipid levels in the blood together with high blood pressure and diabetes are among the highest risks for coronary heart disease. In particular, elevated cholesterol levels promote the progression of atherosclerosis. Red yeast rice, also called red fermented...

Cite
Farkouh A, Baumgärtel C. Mini-review: medication safety of red yeast rice products. Int J Gen Med. 2019;12:167-171doi: 10.2147/IJGM.S202446.
Farkouh, A., & Baumgärtel, C. (2019). Mini-review: medication safety of red yeast rice products. International journal of general medicine, 12167-171. https://doi.org/10.2147/IJGM.S202446
Farkouh, André, and Baumgärtel, Christoph. "Mini-review: medication safety of red yeast rice products." International journal of general medicine vol. 12 (2019): 167-171. doi: https://doi.org/10.2147/IJGM.S202446
Farkouh A, Baumgärtel C. Mini-review: medication safety of red yeast rice products. Int J Gen Med. 2019 Apr 30;12:167-171. doi: 10.2147/IJGM.S202446. eCollection 2019. PMID: 31118742; PMCID: PMC6500871.
Copy Download .nbib Format: NLM
Perceptions of Arguments in Support of Policies to Reduce Sugary Drink Consumption Among Low-Income White, Black and Latinx Parents of Young Children.

American journal of health promotion : AJHP

Cannon JS, Farkouh EK, Winett LB, Dorfman L, Ramírez AS, Lazar S, Niederdeppe J.
PMID: 34269101
Am J Health Promot. 2022 Jan;36(1):84-93. doi: 10.1177/08901171211030849. Epub 2021 Jul 16.

PURPOSE: To test for racial/ethnic differences in perceived argument strength in favor of structural interventions to curb childhood obesity among lower-income parents of young children.DESIGN: Cross-sectional, self-report.SETTING: Online research panel, national sample of 1485 US adults in Fall 2019.PARTICIPANTS:...

Cite
Cannon JS, Farkouh EK, Winett LB, et al. Perceptions of Arguments in Support of Policies to Reduce Sugary Drink Consumption Among Low-Income White, Black and Latinx Parents of Young Children. Am J Health Promot. 2021;36(1):84-93doi: 10.1177/08901171211030849.
Cannon, J. S., Farkouh, E. K., Winett, L. B., Dorfman, L., Ramírez, A. S., Lazar, S., & Niederdeppe, J. (2022). Perceptions of Arguments in Support of Policies to Reduce Sugary Drink Consumption Among Low-Income White, Black and Latinx Parents of Young Children. American journal of health promotion : AJHP, 36(1), 84-93. https://doi.org/10.1177/08901171211030849
Cannon, Julie S, et al. "Perceptions of Arguments in Support of Policies to Reduce Sugary Drink Consumption Among Low-Income White, Black and Latinx Parents of Young Children." American journal of health promotion : AJHP vol. 36,1 (2022): 84-93. doi: https://doi.org/10.1177/08901171211030849
Cannon JS, Farkouh EK, Winett LB, Dorfman L, Ramírez AS, Lazar S, Niederdeppe J. Perceptions of Arguments in Support of Policies to Reduce Sugary Drink Consumption Among Low-Income White, Black and Latinx Parents of Young Children. Am J Health Promot. 2022 Jan;36(1):84-93. doi: 10.1177/08901171211030849. Epub 2021 Jul 16. PMID: 34269101.
Copy Download .nbib Format: NLM
Sex-Related Differences in Drugs with Anti-Inflammatory Properties.

Journal of clinical medicine

Farkouh A, Baumgärtel C, Gottardi R, Hemetsberger M, Czejka M, Kautzky-Willer A.
PMID: 33916167
J Clin Med. 2021 Apr 01;10(7). doi: 10.3390/jcm10071441.

There is increasing evidence of sex differences in the action of anti-inflammatory drugs, with women being at significantly higher risk of adverse effects. Nevertheless, clinicians' awareness of the implications of these sex differences on dosing and adverse event monitoring...

Cite
Farkouh A, Baumgärtel C, Gottardi R, et al. Sex-Related Differences in Drugs with Anti-Inflammatory Properties. J Clin Med. 2021;10(7)doi: 10.3390/jcm10071441.
Farkouh, A., Baumgärtel, C., Gottardi, R., Hemetsberger, M., Czejka, M., & Kautzky-Willer, A. (2021). Sex-Related Differences in Drugs with Anti-Inflammatory Properties. Journal of clinical medicine, 10(7), . https://doi.org/10.3390/jcm10071441
Farkouh, André, et al. "Sex-Related Differences in Drugs with Anti-Inflammatory Properties." Journal of clinical medicine vol. 10,7 (2021). doi: https://doi.org/10.3390/jcm10071441
Farkouh A, Baumgärtel C, Gottardi R, Hemetsberger M, Czejka M, Kautzky-Willer A. Sex-Related Differences in Drugs with Anti-Inflammatory Properties. J Clin Med. 2021 Apr 01;10(7). doi: 10.3390/jcm10071441. PMID: 33916167; PMCID: PMC8037587.
Copy Download .nbib Format: NLM
Association of Adverse Childhood Experiences With Cardiovascular Disease Later in Life: A Review.

JAMA cardiology

Godoy LC, Frankfurter C, Cooper M, Lay C, Maunder R, Farkouh ME.
PMID: 33263716
JAMA Cardiol. 2021 Feb 01;6(2):228-235. doi: 10.1001/jamacardio.2020.6050.

IMPORTANCE: Adverse childhood experiences (ACEs) are potentially harmful events that occur during childhood, spanning neglect, physical or sexual abuse, parental separation, or death, among others. At least 50% of the US adult population has experienced 1 or more ACEs...

Cite
Godoy LC, Frankfurter C, Cooper M, et al. Association of Adverse Childhood Experiences With Cardiovascular Disease Later in Life: A Review. JAMA Cardiol. 2021;6(2):228-235doi: 10.1001/jamacardio.2020.6050.
Godoy, L. C., Frankfurter, C., Cooper, M., Lay, C., Maunder, R., & Farkouh, M. E. (2021). Association of Adverse Childhood Experiences With Cardiovascular Disease Later in Life: A Review. JAMA cardiology, 6(2), 228-235. https://doi.org/10.1001/jamacardio.2020.6050
Godoy, Lucas C, et al. "Association of Adverse Childhood Experiences With Cardiovascular Disease Later in Life: A Review." JAMA cardiology vol. 6,2 (2021): 228-235. doi: https://doi.org/10.1001/jamacardio.2020.6050
Godoy LC, Frankfurter C, Cooper M, Lay C, Maunder R, Farkouh ME. Association of Adverse Childhood Experiences With Cardiovascular Disease Later in Life: A Review. JAMA Cardiol. 2021 Feb 01;6(2):228-235. doi: 10.1001/jamacardio.2020.6050. PMID: 33263716.
Copy Download .nbib Format: NLM
Comparison of Troponin Elevation, Prior Myocardial Infarction, and Chest Pain in Acute Ischemic Heart Failure.

CJC open

Freitas C, Wang X, Ge Y, Ross HJ, Austin PC, Pang PS, Ko DT, Farkouh ME, Stukel TA, McMurray JJV, Lee DS.
PMID: 32462127
CJC Open. 2020 Feb 24;2(3):135-144. doi: 10.1016/j.cjco.2020.02.007. eCollection 2020 May.

BACKGROUND: Patients with heart failure (HF) with concomitant ischemic heart disease (IHD) have not been well characterized. We examined survival of patients with ischemic HF syndrome (IHFS), defined as presentation with acute HF and concomitant features suggestive of IHD.METHODS:...

Cite
Freitas C, Wang X, Ge Y, et al. Comparison of Troponin Elevation, Prior Myocardial Infarction, and Chest Pain in Acute Ischemic Heart Failure. CJC Open. 2020;2(3):135-144doi: 10.1016/j.cjco.2020.02.007.
Freitas, C., Wang, X., Ge, Y., Ross, H. J., Austin, P. C., Pang, P. S., Ko, D. T., Farkouh, M. E., Stukel, T. A., McMurray, J. J. V., & Lee, D. S. (2020). Comparison of Troponin Elevation, Prior Myocardial Infarction, and Chest Pain in Acute Ischemic Heart Failure. CJC open, 2(3), 135-144. https://doi.org/10.1016/j.cjco.2020.02.007
Freitas, Cassandra, et al. "Comparison of Troponin Elevation, Prior Myocardial Infarction, and Chest Pain in Acute Ischemic Heart Failure." CJC open vol. 2,3 (2020): 135-144. doi: https://doi.org/10.1016/j.cjco.2020.02.007
Freitas C, Wang X, Ge Y, Ross HJ, Austin PC, Pang PS, Ko DT, Farkouh ME, Stukel TA, McMurray JJV, Lee DS. Comparison of Troponin Elevation, Prior Myocardial Infarction, and Chest Pain in Acute Ischemic Heart Failure. CJC Open. 2020 Feb 24;2(3):135-144. doi: 10.1016/j.cjco.2020.02.007. eCollection 2020 May. PMID: 32462127; PMCID: PMC7242506.
Copy Download .nbib Format: NLM
ACP Journal Club. Aspirin and/or antioxidants did not prevent CV events in diabetes and peripheral arterial disease.

Annals of internal medicine

Farkouh ME.
PMID: 19172713
Ann Intern Med. 2009 Jan 20;150(2):JC1-8. doi: 10.7326/0003-4819-150-2-200901200-02008.

No abstract available.

Cite
Farkouh ME. ACP Journal Club. Aspirin and/or antioxidants did not prevent CV events in diabetes and peripheral arterial disease. Ann Intern Med. 2009;150(2):JC1-8doi: 10.7326/0003-4819-150-2-200901200-02008.
Farkouh, M. E. (2009). ACP Journal Club. Aspirin and/or antioxidants did not prevent CV events in diabetes and peripheral arterial disease. Annals of internal medicine, 150(2), JC1-8. https://doi.org/10.7326/0003-4819-150-2-200901200-02008
Farkouh, Michael E. "ACP Journal Club. Aspirin and/or antioxidants did not prevent CV events in diabetes and peripheral arterial disease." Annals of internal medicine vol. 150,2 (2009): JC1-8. doi: https://doi.org/10.7326/0003-4819-150-2-200901200-02008
Farkouh ME. ACP Journal Club. Aspirin and/or antioxidants did not prevent CV events in diabetes and peripheral arterial disease. Ann Intern Med. 2009 Jan 20;150(2):JC1-8. doi: 10.7326/0003-4819-150-2-200901200-02008. PMID: 19172713.
Copy Download .nbib Format: NLM
Review: diabetes is not a coronary disease equivalent.

Evidence-based medicine

Farkouh ME.
PMID: 19794011
Evid Based Med. 2009 Oct;14(5):136-7. doi: 10.1136/ebm.14.5.136.

No abstract available.

Cite
Farkouh ME. Review: diabetes is not a coronary disease equivalent. Evid Based Med. 2009;14(5):136-7doi: 10.1136/ebm.14.5.136.
Farkouh, M. E. (2009). Review: diabetes is not a coronary disease equivalent. Evidence-based medicine, 14(5), 136-7. https://doi.org/10.1136/ebm.14.5.136
Farkouh, Michael E. "Review: diabetes is not a coronary disease equivalent." Evidence-based medicine vol. 14,5 (2009): 136-7. doi: https://doi.org/10.1136/ebm.14.5.136
Farkouh ME. Review: diabetes is not a coronary disease equivalent. Evid Based Med. 2009 Oct;14(5):136-7. doi: 10.1136/ebm.14.5.136. PMID: 19794011.
Copy Download .nbib Format: NLM
ACP Journal Club. Review: Diabetes is not a coronary disease equivalent.

Annals of internal medicine

Farkou ME.
PMID: 19687480
Ann Intern Med. 2009 Aug 18;151(4):JC2-6, JC2-7. doi: 10.7326/0003-4819-151-4-200908180-02006.

No abstract available.

Cite
Farkou ME. ACP Journal Club. Review: Diabetes is not a coronary disease equivalent. Ann Intern Med. 2009;151(4):JC2-6, JC2-7doi: 10.7326/0003-4819-151-4-200908180-02006.
Farkou, M. E. (2009). ACP Journal Club. Review: Diabetes is not a coronary disease equivalent. Annals of internal medicine, 151(4), JC2-6, JC2-7. https://doi.org/10.7326/0003-4819-151-4-200908180-02006
Farkou, Michael E. "ACP Journal Club. Review: Diabetes is not a coronary disease equivalent." Annals of internal medicine vol. 151,4 (2009): JC2-6, JC2-7. doi: https://doi.org/10.7326/0003-4819-151-4-200908180-02006
Farkou ME. ACP Journal Club. Review: Diabetes is not a coronary disease equivalent. Ann Intern Med. 2009 Aug 18;151(4):JC2-6, JC2-7. doi: 10.7326/0003-4819-151-4-200908180-02006. PMID: 19687480.
Copy Download .nbib Format: NLM
Dipeptidyl peptidase-4 inhibitors and the risk of heart failure: a systematic review and meta-analysis.

CMAJ open

Verma S, Goldenberg RM, Bhatt DL, Farkouh ME, Quan A, Teoh H, Connelly KA, Leiter LA, Friedrich JO.
PMID: 28459046
CMAJ Open. 2017 Feb 24;5(1):E152-E177. doi: 10.9778/cmajo.20160058. eCollection 2017.

BACKGROUND: Given recent discrepant results from randomized controlled trials (RCTs), we examined the totality of RCT evidence assessing the association between dipeptidyl peptidase-4 (DPP-4) inhibitors and heart failure.METHODS: MEDLINE, Embase and ClinicalTrials.gov were searched without language restrictions to August...

Cite
Verma S, Goldenberg RM, Bhatt DL, et al. Dipeptidyl peptidase-4 inhibitors and the risk of heart failure: a systematic review and meta-analysis. CMAJ Open. 2017;5(1):E152-E177doi: 10.9778/cmajo.20160058.
Verma, S., Goldenberg, R. M., Bhatt, D. L., Farkouh, M. E., Quan, A., Teoh, H., Connelly, K. A., Leiter, L. A., & Friedrich, J. O. (2017). Dipeptidyl peptidase-4 inhibitors and the risk of heart failure: a systematic review and meta-analysis. CMAJ open, 5(1), E152-E177. https://doi.org/10.9778/cmajo.20160058
Verma, Subodh, et al. "Dipeptidyl peptidase-4 inhibitors and the risk of heart failure: a systematic review and meta-analysis." CMAJ open vol. 5,1 (2017): E152-E177. doi: https://doi.org/10.9778/cmajo.20160058
Verma S, Goldenberg RM, Bhatt DL, Farkouh ME, Quan A, Teoh H, Connelly KA, Leiter LA, Friedrich JO. Dipeptidyl peptidase-4 inhibitors and the risk of heart failure: a systematic review and meta-analysis. CMAJ Open. 2017 Feb 24;5(1):E152-E177. doi: 10.9778/cmajo.20160058. eCollection 2017. PMID: 28459046; PMCID: PMC5403656.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 76 entries